In clinical settings, a study involving patients with metastatic melanoma undergoing immunotherapy showed that CD8 PET tracer (89Zr-Df-IAB22M2C, performed 28 days after immunotherapy) was noticeably incorporated during metastases, indicating infiltration of CD8+ T cells. Here, CD8A is linked to metastatic melanoma.